Omeros Corporation

NasdaqGM:OMER Stock Report

Market Cap: US$349.4m

Omeros Valuation

Is OMER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OMER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OMER's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OMER's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OMER?

Key metric: As OMER is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for OMER. This is calculated by dividing OMER's market cap by their current book value.
What is OMER's PB Ratio?
PB Ratio-2.3x
Book-US$154.17m
Market CapUS$349.44m

Price to Book Ratio vs Peers

How does OMER's PB Ratio compare to its peers?

The above table shows the PB ratio for OMER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average8x
CRMD CorMedix
11.1x183.4%US$671.7m
NUVB Nuvation Bio
1.7x41.6%US$871.7m
AVDL Avadel Pharmaceuticals
13.9x64.2%US$1.0b
SCPH scPharmaceuticals
5.5x69.8%US$176.1m
OMER Omeros
n/a39.1%US$349.4m

Price-To-Book vs Peers: OMER has negative equity and a Price-To-Book Ratio (-2.3x) compared to the peer average (9.7x).

Price to Book Ratio vs Industry

How does OMER's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

25 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.82m
UPC Universe Pharmaceuticals
0.1xn/aUS$3.23m
TNFA TNF Pharmaceuticals
0.2xn/aUS$2.71m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.40m
OMER is unprofitableIndustry Avg. 1.7xNo. of Companies25PB012345+
25 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: OMER has negative equity and a Price-To-Book Ratio (-2.3x) compared to the US Pharmaceuticals industry average (1.6x).

Price to Book Ratio vs Fair Ratio

What is OMER's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OMER PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OMER's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%